Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
Company profile
Ticker
GBT
Exchange
Website
CEO
Ted Love
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
GBT stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
17 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
5 Oct 22
Transcripts
GBT
Earnings call transcript
2022 Q1
5 May 22
GBT
Earnings call transcript
2021 Q4
24 Feb 22
GBT
Earnings call transcript
2021 Q3
5 Nov 21
GBT
Earnings call transcript
2021 Q2
4 Aug 21
GBT
Earnings call transcript
2021 Q1
6 May 21
GBT
Earnings call transcript
2020 Q4
28 Feb 21
GBT
Earnings call transcript
2020 Q3
5 Nov 20
GBT
Earnings call transcript
2020 Q2
5 Aug 20
GBT
Earnings call transcript
2020 Q1
6 May 20
GBT
Earnings call transcript
2019 Q4
26 Feb 20
Financial summary
| Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 263.58 mm | 263.58 mm | 263.58 mm | 263.58 mm | 263.58 mm | 263.58 mm |
| Cash burn (monthly) | 43.56 mm | 13.18 mm | 27.43 mm | 26.15 mm | 14.77 mm | 20.78 mm |
| Cash used (since last report) | 312.98 mm | 94.68 mm | 197.07 mm | 187.89 mm | 106.12 mm | 149.34 mm |
| Cash remaining | -49.39 mm | 168.90 mm | 66.52 mm | 75.69 mm | 157.46 mm | 114.25 mm |
| Runway (months of cash) | -1.1 | 12.8 | 2.4 | 2.9 | 10.7 | 5.5 |
Institutional ownership, Q3 2022
96.1% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 244 |
| Opened positions | 113 |
| Closed positions | 63 |
| Increased positions | 54 |
| Reduced positions | 57 |
| 13F shares | Current |
|---|---|
| Total value | 4.42 bn |
| Total shares | 64.88 mm |
| Total puts | 1.05 mm |
| Total calls | 1.89 mm |
| Total put/call ratio | 0.6 |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 6.28 mm | $427.82 mm |
| BLK Blackrock | 4.75 mm | $323.47 mm |
| Baker Bros. Advisors | 3.73 mm | $254.18 mm |
| Pentwater Capital Management | 3.20 mm | $217.92 mm |
| Perceptive Advisors | 2.32 mm | $158.15 mm |
| JPM JPMorgan Chase & Co. | 2.30 mm | $156.95 mm |
| FIL | 2.26 mm | $154.11 mm |
| Ubs Oconnor | 2.24 mm | $152.46 mm |
| GS Goldman Sachs | 1.71 mm | $116.22 mm |
| C Citigroup | 1.59 mm | $108.03 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 5 Oct 22 | Kim Smith-Whitley | Common Stock | Sale back to company | Dispose D | No | No | 0 | 5,980 | 0.00 | 0 |
| 5 Oct 22 | Kim Smith-Whitley | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 29.87 | 28,628 | 855.12 k | 0 |
| 5 Oct 22 | Kim Smith-Whitley | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 37.2 | 35,500 | 1.32 mm | 0 |
| 5 Oct 22 | Kim Smith-Whitley | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 42,400 | 0.00 | 0 |
| 5 Oct 22 | Kim Smith-Whitley | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 26,454 | 0.00 | 0 |
| 5 Oct 22 | Kim Smith-Whitley | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 15,460 | 0.00 | 0 |
| 5 Oct 22 | Kim Smith-Whitley | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 18,120 | 0.00 | 0 |
| 5 Oct 22 | Choi Jung | Common Stock | Sale back to company | Dispose D | Yes | No | 0 | 25,000 | 0.00 | 0 |
| 5 Oct 22 | Choi Jung | Common Stock | Sale back to company | Dispose D | No | No | 0 | 226,672 | 0.00 | 0 |
| 5 Oct 22 | Choi Jung | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 29.87 | 28,628 | 855.12 k | 0 |